Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort

高眼压治疗研究队列的长期生活质量

• 批准号: 10667711
• 负责人: MAE O GORDON
• 金额: $ 24.63万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667711
• 关键词: Affect; Age; Automobile Driving; Benefits and Risks; Cessation of life; Clinical; Cohort Studies; Contrast Sensitivity; Control Groups; Cross-Sectional Studies; Data; Demographic Factors; Diagnosis; Eye; Glaucoma; Health; Individual Adjustment; Individual Differences; Life; Life Expectancy; Long-Term Effects; Longitudinal cohort; Measures; National Eye Institute; Ocular Hypertension; Ophthalmology; Outcome; Participant; Patients; Primary Open Angle Glaucoma; Protocols documentation; Quality of life; Questionnaires; Reading; Reporting; Sampling; Surveys; Testing; United States Preventative Services Task Force; Vision; Visit; Visual Acuity; Visual Fields; Visual impairment; Walking; age effect; cohort; expectation; follow-up; hypertension treatment; improved; indexing; longitudinal analysis; rate of change; secondary analysis; treatment effect

Project Summary This application is for secondary analyses to determine the long-term effect of treatment, clinical and demographic factors on vision-related quality of life (VRQOL) in the Ocular Hypertension Treatment Study (OHTS) cohort. This application is timely because the US Preventative Services Task Force recently concluded there was “Inadequate evidence that treatment of primary open-angle glaucoma improves health outcomes such as reduced visual impairment, vision-related function, and quality of life” (JAMA Ophthal, May 2022). OHTS is the only US study with 20-year clinical and VRQOL outcomes in a cohort of 1,636 participants with ocular hypertension. The 20 year follow-up is meaningful because it approaches the life expectation of participants whose median age was 55 at baseline. Aim 1 will report cross-sectional 20 year data from the National Eye Institute Visual Function Questionnaire (NEI VFQ) and 15 item Glaucoma Quality Life survey (GQL-15). Aim 2 will focus on longitudinal changes in clinical and VRQOL in the inception cohort of participants who developed POAG in OHTS 1 or 2. Pre-POAG VRQOL data collected in the inception cohort will allow statistical adjustment for individual differences on post-POAG VRQOL which will increase precision of post-POAG impact on VRQOL. Accurate dates of POAG diagnosis in the inception cohort will enable a rigorous test of the effect of duration and rate of change in clinical parameters on VRQOL. We will analyze treatment, clinical and demographic factors affecting VRQOL in the cross-sectional sample at 20 years of follow-up (Aim 1) and in the longitudinal cohort sample (Aim 2). Core tests and measures were completed per protocol at 6 month intervals for 13 years and at 1-3 visits after 20 years of follow-up. Tests and measures to be analyzed include indices from Humphrey 30-2 SITA standard visual fields, best corrected acuity, Pelli-Robson contrast sensitivity, and OCT (assessed at 20 years). VRQOL was assessed using the NEI-VFQ administered every 2 years for 13 years and the GQL-15 administered at 20 years.

项目概要 该应用程序用于二次分析，以确定治疗的长期效果、临床效果 和人口因素对高眼压患者视力相关生活质量 (VRQOL) 的影响 治疗研究 (OHTS) 队列。这个申请很及时，因为美国预防性 服务工作组最近得出结论，“没有足够的证据表明治疗 原发性开角型青光眼可改善健康结果，例如减少视力障碍， 视觉相关的功能和生活质量”（JAMA 眼科杂志，2022 年 5 月）。 OHTS 是美国唯一一项针对 1,636 名受试者进行的 20 年临床和 VRQOL 结果研究 患有高眼压症的参与者。 20年的随访是有意义的，因为它 接近基线时中位年龄为 55 岁的参与者的预期寿命。目标1将 报告来自国家眼科研究所视觉功能问卷的 20 年横截面数据 (NEI VFQ) 和 15 项青光眼生活质量调查 (GQL-15)。目标 2 将重点关注 参与者初始队列中临床和 VRQOL 的纵向变化 在 OHTS 1 或 2 中开发了 POAG。在初始队列中收集的 POAG 前​​ VRQOL 数据将 允许对 POAG 后 VRQOL 的个体差异进行统计调整，这将 提高 POAG 后对 VRQOL 影响的精确度。 POAG 诊断的准确日期 初始队列将能够对临床持续时间和变化率的影响进行严格测试 VRQOL 上的参数。我们将分析影响治疗、临床和人口因素 20 年随访（目标 1）时的横截面样本和纵向样本中的 VRQOL 队列样本（目标 2）。 核心测试和测量按照协议每隔 6 个月完成一次，持续 13 年，并在 1-3 年完成 20年后的随访。要分析的测试和措施包括来自 Humphrey 30-2 SITA 标准视野、最佳矫正视力、Pelli-Robson 对比度 敏感性和 OCT（20 年评估）。使用 NEI-VFQ 评估 VRQOL 每 2 年进行一次，持续 13 年，GQL-15 在 20 年进行一次。